Swiss trade group objects to cost containment measures

Interpharma, the association of research-based pharmaceutical companies in Switzerland, has called on lawmakers to reconsider a cost containment package which it says “is putting patient access at risk.”

In a statement, the group responded to plans from The Council of States Health Commission (SGK-S) to introduce so-called cost follow-up models.

Interpharma said that the introduction of these models in the pricing of medicines was being made without proper consultation or analysis having been undertaken.